Bloomberg Podcasts
@bloombergpodcasts·503K subscribers·32.4K videos
Steel Stocks Movers; Bristol Myers Deal; BYD Downswing | Stock Movers
Posted
June 2, 2025
Views
741
Likes
2
Engagement
0.27%
June 2, 2025
741
2
0.27%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
4:06Now PlayingOn this episode of Stock Movers:
- US Steel (X) shares are weaker this morning on news that President Trump is threatening to raise steel and aluminum tariffs. President Trump announced that he would increase tariffs on steel and aluminum to 50% from 25%, saying the move would help protect American workers. The deal would ensure the iconic American firm remains US-owned and operated, with Trump promising that US Steel workers would receive a $5,000 bonus and that $2.2 billion of the proposed investment would be earmarked to increase steel production.
- Cleveland Cliffs (CLF) is moving in the opposite direction of its competitor this morning as its rising on the tariff news. The president made the announcement during a visit to a United States Steel Corp. plant near Pittsburgh, where he championed an expected deal between US Steel and Japan's Nippon Steel Corp.
- BYD (BYDDY) shares fell due to concerns that its price cuts are drawing government scrutiny and becoming unsustainable for the Chinese EV industry. The Chinese government and industry associations have expressed concerns about the "rat-race competition" and "vicious competition" in the auto sector, warning that it could hurt profit margins and product quality.
- Bristol Myers (BMY) is higher this morning along with the broader pharma sector as it agrees to pay BioNTech SE up to $11.1 billion to license a next-generation cancer drug, with $1.5 billion upfront and $2 billion in installments through 2028. The deal marks a major payoff for BioNTech, which initially licensed the compound from Chinese biotech Biotheus in 2023 and later bought the company outright for up to $950 million.
See omnystudio.com/listener () for privacy information.
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.
Check out more episodes of Stock Movers
Follow Bloomberg Podcasts on Twitter
Visit our other YouTube channels:
Bloomberg Television
Bloomberg Originals
For coverage on news, markets and more
#Stocks #Markets #Finance #Investing #Podcast #Bloomberg
Steel Stocks Movers; Bristol Myers Deal; BYD Downswing
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
